TITLE

Alzheimer's disease

AUTHOR(S)
Masters, Colin L.; Beyreuther, Konrad
PUB. DATE
February 1998
SOURCE
BMJ: British Medical Journal (International Edition);02/07/98, Vol. 316 Issue 7129, p446
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Provides information on the occurrence of Alzheimer's disease, an organic mental disorder in adults. Causes of Alzheimer's; Rick factors of the disease; Therapeutic measures for the treatment of Alzheimer's disease. INSETS: Possible features;Neurodegenerative diseases associated with abnormal protein...;Managing alzheimer's disease in the year 2008;Therapeutic targets in the amyloidogenic pathway
ACCESSION #
298524

 

Related Articles

  • donepezil.  // Davis's Drug Guide for Nurses, 10th edition;2007, p421 

    The article presents a nursing guide to donepezil, an anti-Alzheimer's agent for the treatment of mild to moderate dementia. Its mechanism of action and pharmacokinetics are explained. Contraindications for the drug are presented. Its adverse reactions are cited. Nursing implications are also...

  • Research briefs: Daffodils good for the memory.  // GP: General Practitioner;11/4/2005, p6 

    This article reports that daffodils can be used to manufacture a treatment for Alzheimer's disease. It is informed that researchers at Cardiff University's Manufacturing Engineering Center are planning to set up daffodil farms in the mountains of Wales to be used in the manufacture of galantamine.

  • Trial design innovations: Clinical trials for treatment of neuropsychiatric symptoms in Alzheimer's Disease. Cummings, J; Zhong, K // Clinical Pharmacology & Therapeutics;Nov2015, Vol. 98 Issue 5, p483 

    Neuropsychiatric symptoms are common in Alzheimer's disease (AD) and other neurodegenerative disorders. Recent progress has been made with clinical trials, advancing new therapies for psychosis in Parkinson's disease (PD), agitation in AD, and apathy in AD. Definitions have emerged for agitation...

  • Second-generation antipsychotics in dementia: beyond safety concerns. A clinical, systematic review of efficacy data from randomised controlled trials. Gentile, Salvatore // Psychopharmacology;Oct2010, Vol. 212 Issue 2, p119 

    Rationale: Antipsychotic drugs are widely used as a first-line pharmacological approach to treat dementia-related psychiatric symptoms. However, in this population of patients, such drugs have been associated with severe safety concerns. Hence, the aim of this review is to asses systematically...

  • Memory Loss, Dementia and Alzheimer's Disease. Gaeddert, Andrew // Oriental Medicine Journal;Summer2004, Vol. 12 Issue 4, p14 

    This article focuses on the management of Alzheimer's disease (AD) and other conditions involving poor memory and dementia. Dementia is a condition in which memory, thinking, judgment and the ability to concentrate are impaired. Dementia may be resulted due to severe injury, disease, or...

  • Dietary approach for cognitive and behavioral problems in dementia. Bhandari, Prasan R. // International Journal of Nutrition, Pharmacology, Neurological D;Oct2013, Vol. 3 Issue 4, p398 

    The article discusses a dietary approach for cognitive and behavioral problems in dementia. It describes the anti-amyloidogenic effect of a carotenoid from the stigma of the saffron flower called crocin. It also offers information on other common dietary ingredients that have a beneficial effect...

  • Forest: disappointing results for pipeline Alzheimer's drug.  // PharmaWatch: CNS;October 2004, Vol. 3 Issue 10, p7 

    The article presents information about Forest & Co., which has announced the results of its phase III trial for neramexane, a drug for the potential treatment of Alzheimer's disease (AD). The results will come as a disappointment to Forest, which has already suffered a number of delays gaining...

  • Tracking Washington.  // MondayMorning;2/27/2012, Vol. 20 Issue 9, p1 

    The article reports on the efforts made by the U.S. government to fight the problems caused due to the Alzheimer's disease and to find a treatment by the year 2025. As stated, there is no treatment for the disease and therefore, the country's government is planning to invest in a research for...

  • 10 NEUROLOGIC DISORDERS 10A Alzheimer's dementia.  // Monthly Prescribing Reference;Oct2016, Vol. 32 Issue 10, p162 

    The article offers information on the medications for the treatment of Alzheimer's dementia from different pharmaceutical companies that includes Forest, Janssen and Actavis. It mentions its indications and symptoms, contraindications and precautions for each medications. Moreover, it also cites...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics